Petr Jelinek

Dr. Petr Jelinek

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2022 in Medical Science Monitor
Verified
Journal Article
Open access
JRJan Roman
Jan Roman
FJFrantišek Jalůvka
František Jalůvka
POPetr Ostruszka
Petr Ostruszka
PJPetr Jelinek
Petr Jelinek
JHJán Hrubovčák
Ján Hrubovčák
VPVaclav Prochazka
Vaclav Prochazka
Kidney donation after circulatory death (DCD) follows confirmation of death using cardiorespiratory criteria, while donation after brain death (DBD) uses neurological criteria. DBD and DCD donors are the main sources of grafts for transplantation. This retrospective cohort study from a single center in the Czech Republic aimed to compare 5-year post-transplantation outcomes after DCD and DBD transplantation without pre-mortem heparin administration. A total of 227 recipients with matched donors enrolled in the transplantation program at our institution between 2015 and 2019 were analyzed. Following the application of the inclusion criteria, 99 recipients and 94 matched donors were finally included in the study. The duration of cold ischemia (median 961 vs 1100 min, P=0.028) and the perfusion with the preservation solution (median 11 vs 22 min, P<0.001) was statistically significantly shorter in DBD than in DCD grafts. The 1-year survival rates were 97.5% (95% CI 94.1–100.0%) and 90.0% (95% CI: 77.8–100.0%) for DBD and DCD recipients, respectively. The 3-year survival rates were 91.9 (95% CI: 86.0–98.4) and 90.0 (95% CI: 77.8–100.0) for the DBD and DCD groups, respectively. The overall difference in survival between the 2 groups of patients was not statistically significant (P=0.750) nor was disease-free survival (P=0.370). This retrospective study from a single center showed similar 5-year results after kidney transplantation for DCD and DBD donors without pre-mortem heparin administration, including the time to graft failure and patient survival.

22 September 2024 in Medicina
Verified
Journal Article
Open access
PDF file
PJPetr Jelinek
Petr Jelinek
JHJan Hrubovcak
Jan Hrubovcak
RHRadovan Hajovsky
Radovan Hajovsky
JVJan Velička
Jan Velička
MPMartin Pies
Martin Pies
Background and Objectives: Surgical site infections (SSIs) are a significant complication following ventral hernia repair, potentially leading to prolonged hospital stays and increased morbidity. This study aimed to evaluate whether closed incision negative pressure wound therapy (ciNPWT) reduces the incidence of SSI after ventral hernia repair with polypropylene mesh compared to standard wound care. Materials and Methods: A randomized study was conducted with 100 patients undergoing ventral hernia repair using a polypropylene mesh. Participants were divided into two groups: a control group (n=50), which received standard sterile gauze dressing with an iodine-based disinfectant, and an intervention group (n=50), treated with the ciNPWT system (Vivano® by HARTMANN) for 5 days postoperatively. The primary outcome was the incidence of SSI within one year after surgery. Secondary outcomes included the influence of factors such as age, sex, smoking status, and hernia size on SSI occurrence. The study was approved by the Ethics Committee at the University Hospital Ostrava, adhering to the ethical standards of the Helsinki Declaration. Results: The incidence of SSI was lower in the ciNPWT group compared to the standard care group (4% vs. 12%), though this difference did not reach statistical significance. No significant effect of sex or smoking status on SSI was observed. The control group had a shorter mean length of hospital stay. Larger hernias in the non-ciNPWT group were more prone to SSIs, as expected. Conclusions: Although limited by a small sample size, the findings suggest that ciNPWT may be associated with a reduced rate of SSI following ventral hernia repair. Further studies with larger populations are needed to confirm these results.

30 December 2025 in Annals of Transplantation
Verified
Journal Article
Open access
JRJan Roman
Jan Roman
FJFrantišek Jalůvka
František Jalůvka
PJPetr Jelinek
Petr Jelinek
POPetr Ostruszka
Petr Ostruszka
JHJán Hrubovčák
Ján Hrubovčák
VPVaclav Prochazka
Vaclav Prochazka
BACKGROUND The Coronavirus disease 2019 (COVID-19) pandemic disrupted transplant programs worldwide. Transplant recipients are especially vulnerable to the effects of SARS-CoV-2 infection due to immunosuppression. This study assessed the impact of the COVID-19 pandemic on kidney transplant outcomes. MATERIAL AND METHODS We performed a single-center, retrospective cohort study of the kidney transplant program in the Czech Republic. The analysis included 145 recipients transplanted from 138 donors between 2015 and 2022. Cohorts were defined by donor procurement before the pandemic (n=94) or during the pandemic (n=44). The analysis focused on short- and long-term graft and patient outcomes of both groups. RESULTS No significant differences were found in postoperative kidney graft function (P=0.160) or overall survival before and during the pandemic. The 1- and 3-year survival rates before the pandemic were 96.0% and 90.9%. During the pandemic, they were 97.8% at both time points (P=0.092). Deathcensored failure-free survival was 95.9% and 90.4% at 1 and 3 years before the pandemic versus 95.6% at 1 and 3 years during the pandemic, respectively (P=0.377). Estimated glomerular filtration rate at 7 days (P=0.233) and 1 month (P=0.893) did not differ between vaccinated and non-vaccinated recipients. CONCLUSIONS The COVID-19 pandemic had no significant impact on the short- or long-term outcomes of the kidney transplantation program. These data support sustaining standard kidney transplantation programs during health crises.

6 January 2026 in Medical Science Monitor
Verified
Journal Article
Open access
JRJan Roman
Jan Roman
FJFranišek Jalůvka
Franišek Jalůvka
FBFilip Burša
Filip Burša
PJPetr Jelinek
Petr Jelinek
POPetr Ostruszka
Petr Ostruszka
VPVaclav Prochazka
Vaclav Prochazka
ECMO-Assisted In-Situ Normothermic Perfusion for Donation After Circulatory Determination of Death Kidney Transplantation: A Narrative Review - Article abstract #950817